Customers - Stemnovate

OVERVIEW

Pharmaceutical industry is facing huge challenge not only from the infectious diseases that require better treatments but also the non-communicable diseases (NCDs). According to WHO, NCDs are by far the leading cause of death worldwide. In 2016, they were responsible for 71% (41 million) of the 57 million deaths which occurred globally. The major NCDs responsible for these deaths included cardiovascular diseases, cancers diabetes and liver related conditions such as Non-alcoholic fatty liver disease (NAFLD)(https://www.who.int/nmh/publications/ncd-profiles-2018/en/. According to FDA, there has to be a disruption in the way drugs are developed to meet the demand for precision medicine and hence the strategies being explored include big data, biological information and cutting-edge analytics.

PHARMA

The process of bringing a medicine to the market is a long, difficult and costly process which takes between 10-15 years, from initial discovery in the laboratory, through the phases of clinical testing to being licensed and available on the market. Drug-Induced Liver Injury (DILI) remains the leading cause of attrition of compounds in drug development and is currently difficult to predict using in vitro cytotoxicity screening and animal studies.

The risks of ‘silent’ hepatotoxic drugs getting introduced into clinical trials, is very high garnering huge financial losses for drug companies through withdrawals and late stage clinical failures.

CRO

Drug toxicity remains a crucial aspect to drug discovery and development in the pharmaceutical industry. The use of animal models and cell lines in most cases result in delayed or failed early to late preclinical phase.

SME

The process of bringing a medicine to the market is a long, difficult and costly process which takes between 10-15 years, from initial discovery in the laboratory, through the phases of clinical testing to being licensed and available on the market. Drug Induced Liver Injury (DILI) remains the leading cause of attrition of compounds in drug development and is currently difficult to predict using in vitro cytotoxicity screening and animal studies.

Our clients say

You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.“

Volunteer

Volunteer for blood donation for liver research

Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!“

Academic Institution

University of Bern

CASE STUDIES & Partnership

Partnering for advanced engineering and measurement standards

Stemnovate has partnered with National Physical Laboratory for advancing the biosensing technology and exploring the novel technologies for imaging of complex cellular models.

25.10.2019

Partnering for European Space Agency Microgravity Application Promotion Programme

Stemnovate has partnered with multinational collaborators on a project coordinated by MEDES Institute of space medicine and physiology.

25.10.2019